Expression Of Serum Visfatin In Patients With Liver, Colon Or Pancreas Cancer And Its Meanings

ObjectiveTo study the changes of visfatin expression in serum of patients with liver, colon or pancreas cancer, in order to find out the association between visfatin expression and nutritional status or prognosis, and to explore the relationship with the anti-tumor therapy.MethodsFasting blood serum visfatin and carcino-embryonic antigen were measured by ELISA and RIA in185cases, including primary liver cancer, colon cancer, pancreas cancer, patients one week after surgery and normal controls, related biochemical variables reflecting the body’s nutritional status were detected with an automatic biochemistry analyzer, related physical indices were also need to measure, and analyze the data by t-test, ANOVA, analysis of covariance and Spearman correlation analysis.Results1. Serum visfatin concentration in primary liver cancer, colon cancer and pancreas cancer were significantly higher than that in controls [(76.987±83.150、35.283±84.373、21.019±8.935)μg/L vs (7.334±5.846)μg/L,P<0.05],while serum visfatin of stage Ⅲ and Ⅳ in3groups were significantly higher than that in stage Ⅰ and Ⅱ[(132.28±84.69、69.44±126.09、27.34±7.68) μg/L vs (18.78±7.24、11.64±3.49、15.15±5.31)μg/L,P<0.05]; Serum visfatin in postoperative group was significantly lower than that in appropriate preoperative group [(5.782±6.745)μg/L vs (47.639±87.399)μg/L,P<0.05].2. Serum CEA concentration in colon cancer group was significantly higher than that in controls [(10.061±12.424)μg/L vs (1.199±0.753)μg/L,P<0.05], while serum CEA of stage Ⅲ and Ⅳ in colon cancer group was significantly higher than that in stage Ⅰ andⅡ[(16.58±16.46)μg/L vs (5.55±5.42)μg/L,P<0.05]; Primary liver cancer group and pancreas cancer group were lower than that in controls [(1.179±0.7040.985±0.595)μg/L vs (1.199±0.753)μg/L], but P>0.05, while serum CEA of stage III and Ⅳ in primary liver cancer group and pancreas cancer group were lower than that in stage I and Ⅱ[(1.18±0.78、0.84±0.64) μg/Lvs (1.18±0.63、1.12±0.54) ng/L], but P>0.05.3.Serum PA, TP and ALB in primary liver cancer group, colon cancer group and pancreas cancer group were significantly lower than that in controls [(122.892±56.258、198.714±50.587、159.611±39.242) g/Lvs (241.613±45.836) g/L, P<0.05];[(51.10±2.404、53.14±3.232、49.37±2.604) g/L vs (61.31±4.962) g/L, P<0.05];[(26.79±2.15428.98±2.94、24.96±3.006) g/L vs (39.13±4.326) g/L, P<0.05]; Serum TG in3groups were higher than that in controls, but P<0.05in colon group[(0.964±0.454) mmol/L vs (0.675±0.527) mmol/L, P<0.05], P>0.05in primary liver cancer group and pancreas cancer group [(0.737±0.241、0.827±0.380) mmol/L vs (0.675±0.527) mmol/L]; Serum TC in primary liver cancer was higher than that in controls[(3.944±0.923) mmol/L vs (2.958±1.886) mmol/L, P<0.05], while colon cancer and pancreas cancer groups were lower than that in controls[(2.846±0.961、3.094±1.070) mmol/L vs (2.958±1.886) mmol/L], but P>0.05.4.The BMI and WHR of3groups were significantly lower than that in controls [(21.72±2.491、20.81±1.975、22.08±1.681) vs (24.41±3.328), P<0.05];[(0.818±0.015、0.817±0.017、0.818±0.016) vs (0.851±0.049), P<0.05].5.Partial correlation analysis showed that the visfatin in3groups and normal group were positively correlated with PA, TP, ALB, BMI and WHR, and negatively correlated with TG and TC.ConclusionVisfatin may become a new broad-spectrum tumor marker, also may be a new indicator for evaluating the body’s nutritional status and determining the patients’ prognosis, while providing new targets in looking for drugs which can cure tumors.